ILK and breast carcinoma: Collectively these findings together with our studies suggest that integrin β1-ILK signaling pathway is required for feedback activation of AKT and can function as an alternative pathway, independent of EGFR in metastatic breast cancer cells to stimulate motility following MEK suppression.